323 related articles for article (PubMed ID: 28703283)
1. Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas.
Janovská P; Bryja V
Br J Pharmacol; 2017 Dec; 174(24):4701-4715. PubMed ID: 28703283
[TBL] [Abstract][Full Text] [Related]
2. Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia.
Janovska P; Poppova L; Plevova K; Plesingerova H; Behal M; Kaucka M; Ovesna P; Hlozkova M; Borsky M; Stehlikova O; Brychtova Y; Doubek M; Machalova M; Baskar S; Kozubik A; Pospisilova S; Pavlova S; Bryja V
Clin Cancer Res; 2016 Jan; 22(2):459-69. PubMed ID: 26240275
[TBL] [Abstract][Full Text] [Related]
3. Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL).
Uhrmacher S; Schmidt C; Erdfelder F; Poll-Wolbeck SJ; Gehrke I; Hallek M; Kreuzer KA
Leuk Res; 2011 Oct; 35(10):1360-6. PubMed ID: 21531460
[TBL] [Abstract][Full Text] [Related]
4. Assembly and architecture of the Wnt/β-catenin signalosome at the membrane.
DeBruine ZJ; Xu HE; Melcher K
Br J Pharmacol; 2017 Dec; 174(24):4564-4574. PubMed ID: 28941231
[TBL] [Abstract][Full Text] [Related]
5. Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology.
Kagey MH; He X
Br J Pharmacol; 2017 Dec; 174(24):4637-4650. PubMed ID: 28574171
[TBL] [Abstract][Full Text] [Related]
6. ROR1 expression is not a unique marker of CLL.
Barna G; Mihalik R; Timár B; Tömböl J; Csende Z; Sebestyén A; Bödör C; Csernus B; Reiniger L; Peták I; Matolcsy A
Hematol Oncol; 2011 Mar; 29(1):17-21. PubMed ID: 20597086
[TBL] [Abstract][Full Text] [Related]
7. Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia.
Khan AS; Hojjat-Farsangi M; Daneshmanesh AH; Hansson L; Kokhaei P; Österborg A; Mellstedt H; Moshfegh A
Tumour Biol; 2016 Sep; 37(9):11947-11957. PubMed ID: 27086035
[TBL] [Abstract][Full Text] [Related]
8. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
9. Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia.
Mangolini M; Götte F; Moore A; Ammon T; Oelsner M; Lutzny-Geier G; Klein-Hitpass L; Williamson JC; Lehner PJ; Dürig J; Möllmann M; Rásó-Barnett L; Hughes K; Santoro A; Méndez-Ferrer S; Oostendorp RAJ; Zimber-Strobl U; Peschel C; Hodson DJ; Schmidt-Supprian M; Ringshausen I
Nat Commun; 2018 Sep; 9(1):3839. PubMed ID: 30242258
[TBL] [Abstract][Full Text] [Related]
10. Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV.
Poppova L; Janovska P; Plevova K; Radova L; Plesingerova H; Borsky M; Kotaskova J; Kantorova B; Hlozkova M; Figulova J; Brychtova Y; Machalova M; Urik M; Doubek M; Kozubik A; Pospisilova S; Pavlova S; Bryja V
Br J Haematol; 2016 Dec; 175(5):851-859. PubMed ID: 27651098
[TBL] [Abstract][Full Text] [Related]
11. WNT signalling: mechanisms and therapeutic opportunities.
Schulte G; Bryja V
Br J Pharmacol; 2017 Dec; 174(24):4543-4546. PubMed ID: 29235106
[TBL] [Abstract][Full Text] [Related]
12. WNT signalling events near the cell membrane and their pharmacological targeting for the treatment of cancer.
Driehuis E; Clevers H
Br J Pharmacol; 2017 Dec; 174(24):4547-4563. PubMed ID: 28244067
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological interventions in the Wnt pathway: inhibition of Wnt secretion versus disrupting the protein-protein interfaces of nuclear factors.
Zimmerli D; Hausmann G; Cantù C; Basler K
Br J Pharmacol; 2017 Dec; 174(24):4600-4610. PubMed ID: 28521071
[TBL] [Abstract][Full Text] [Related]
14. Molecular regulation and pharmacological targeting of the β-catenin destruction complex.
van Kappel EC; Maurice MM
Br J Pharmacol; 2017 Dec; 174(24):4575-4588. PubMed ID: 28634996
[TBL] [Abstract][Full Text] [Related]
15. 'Lnc'-ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signalling.
Ong MS; Cai W; Yuan Y; Leong HC; Tan TZ; Mohammad A; You ML; Arfuso F; Goh BC; Warrier S; Sethi G; Tolwinski NS; Lobie PE; Yap CT; Hooi SC; Huang RY; Kumar AP
Br J Pharmacol; 2017 Dec; 174(24):4684-4700. PubMed ID: 28736855
[TBL] [Abstract][Full Text] [Related]
16. Post-translational modifications regulate signalling by Ror1.
Kaucká M; Krejčí P; Plevová K; Pavlová S; Procházková J; Janovská P; Valnohová J; Kozubík A; Pospíšilová S; Bryja V
Acta Physiol (Oxf); 2011 Nov; 203(3):351-62. PubMed ID: 21481194
[TBL] [Abstract][Full Text] [Related]
17. Winding back Wnt signalling: potential therapeutic targets for treating gastric cancers.
Flanagan DJ; Vincan E; Phesse TJ
Br J Pharmacol; 2017 Dec; 174(24):4666-4683. PubMed ID: 28568899
[TBL] [Abstract][Full Text] [Related]
18. Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma.
Pizzi M; Trentin L; Visentin A; Saraggi D; Martini V; Guzzardo V; Righi S; Frezzato F; Piazza F; Sabattini E; Semenzato G; Rugge M
Hum Pathol; 2019 Mar; 85():251-259. PubMed ID: 30458196
[TBL] [Abstract][Full Text] [Related]
19. CD200 Expression in Diagnostic and Prognostic Assessment of Mature B Cell Lymphophoproliferative Neoplasms.
El Din Fouad NB; Ibrahim NY; Abdel Aziz RS; Ibrahim SK
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3383-3392. PubMed ID: 30583344
[TBL] [Abstract][Full Text] [Related]
20. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V; Mraz M
Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
